Primary Pulmonary Hypertension
The Risk and Benefit of Lung Biopsy Pascal Nicod, MD, and Kenneth M. Moser, MD Among the many enigmas in cardiopulmonary medicine, primary pulmonary hypertension (PPH) holds a prominent place. Such prominence derives from the disquieting yet challenging recognition that its pathogenesis remains unknown; it usually eludes diagnosis for several years; no satisfactory therapy exists; and its prognosis in the individual patient is uncertain. [1] [2] [3] See pp 1198 and 1207 In an effort to resolve some of these questions, Can lung biopsy aid in confirming the diagnosis? The answer seems to be only to a minor degree and with a pitfall involved. The occurrence of the same lesions in other forms of pulmonary hypertension is the pitfall. This pitfall is a deep one in the case of chronic, large vessel thromboembolic hypertension in which a PPH biopsy may deflect the physician from performing angiography20 and considering potential corrective surgery.'2,21 The small gains provided by biopsy would include the identification of pulmonary venoocclusive disease (for which no medical therapy exists),22 of vasculitis, and of unsuspected interstitial fibrotic disease. The last, however, should be detectable by methods other than open lung biopsy.
The potential value of tissue to define prognosis is suggested both by the two reports in this issue4,5 and by previous reports.3 '7'8"18 Plexiform lesions and intimal thickening appear to predict shorter survival from the time of biopsy. However, perhaps such lesions reflect a longer prediagnosis duration of PPH because the onset of PPH usually is difficult to define with any precision. Whatever the case, wide individual variability in prognosis exists despite the presence or absence of plexiform and other lesions.
Thus, viewed in broad context, the clinical impact of open lung biopsy is quite limited, even when expert vascular pathologists review the slides. In the individual patient, the information to be gained must be carefully weighed against the risks. There are two risks: the morbidity and mortality of the procedure itself and the effect of open biopsy on future transplantation decisions. While the immediate risks appear modest, they exist,4 and the procedure should certainly not be undertaken lightly. More critical, perhaps, is the fact that a previous thoracotomy is considered a relative contraindication to lung or heart-lung transplantation because of the pleural scarring induced. With the growing consideration of transplantation in patients with PPH who fail medical therapy-and long current waiting lists-this concern must condition biopsy decisions.23 Given the current situation, then, the riskto-benefit ratio of open lung biopsy in PPH remains quite uncertain. If it is undertaken, the indications should be clear, the risks discussed, and the biopsy reviewed by highly experienced eyes.
